Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 101–200 of 1,001
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276
“As described above, CD4 T-cell responses that are specific for neoantigens exert their helper function at the level of the DC and enhance the activation of antitumor CD8 T cells [61].”
BackgroundInfluentialComputational genomics tools for dissecting tumour–immune cell interactions
Hackl, H., Charoentong, P., Finotello, F., & Trajanoski, Z. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.67 · Cited by 270
“Measure of how much T cell receptors are prone to interact with specific major- histocompatibility-complex-binding peptides.”
BackgroundTumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Fankhauser, M., Broggi, M. A. S., Potin, L., Bordry, N., Jeanbart, L., Lund, A. W., Da Costa, E., Hauert, S., Rincon-Restrepo, M., Tremblay, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4712 · Cited by 259
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., et al. (2017) · Nature · doi:10.1038/nature21433 · Cited by 261
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Lhuillier, C., Rudqvist, N.-P., Yamazaki, T., Zhang, T., Charpentier, M., Galluzzi, L., Dephoure, N., Clement, C. C., Santambrogio, L., Zhou, X. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138740 · Cited by 240
“While the antitumor immune response against neoantigens expressed by solid tumors is predominantly attributed to CD8+ T cells, CD4+ T cells are also important drivers of antitumor immunity (25, 38, 39).”
BackgroundDarragh, L. B., Gadwa, J., Pham, T. T., Van Court, B., Neupert, B., Olimpo, N. A., Nguyen, K., Nguyen, D., Knitz, M. W., Hoen, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34676-w · Cited by 235
“MHC II binding antigens, which are presented only to CD4 T cells, were also recently used to vaccinate patients against cancer 41 .”
Metallic nanoparticles for cancer immunotherapy
Evans, E. R., Bugga, P., Asthana, V., & Drezek, R. (2018) · Materials Today · doi:10.1016/j.mattod.2017.11.022 · Cited by 244
Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V., Esaulova, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.003 · Cited by 234
“This concept, known as epitope spread, has been reported in a number of studies assessing T cell responses to vaccines (Corbiere et al., 2011; Kreiter et al., 2015; Ott et al., 2020; Hu et al., 2021).”
BackgroundDeveloping neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Wang, R.-F., & Wang, H. Y. (2017) · Cell Research · doi:10.1038/cr.2016.155 · Cited by 225
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.012 · Cited by 240
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
“Recent studies have shown that neoantigen vaccine approaches are able to induce robust antitumor responses in mice [33, 40, 47].”
BackgroundMethodInfluentialWard, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2024) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 212
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 229
New opportunities for nanoparticles in cancer immunotherapy
Park, W., Heo, Y.-J., & Han, D. K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0133-y · Cited by 216
Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C., Hebert, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7804 · Cited by 215
“B16F10 cell lines engineered to express the fulllength OVA antigen (B16F10-OVA) were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS), and B16F10-luc cells (40) were cultured in complete media plus puromycin (0.”
MethodSelf-citationCancer immunotherapy targeting neoantigens
Lu, Y.-C., & Robbins, P. F. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 223
Probiotic neoantigen delivery vectors for precision cancer immunotherapy
Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08033-4 · Cited by 198
“The formulation and administration of SLP vaccines was adapted from previous studies 15,79,80 .”
InfluentialMulti-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Schrörs, B., Boegel, S., Albrecht, C., Bukur, T., Bukur, V., Holtsträter, C., Ritzel, C., Manninen, K., Tadmor, A. D., Vormehr, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01195 · Cited by 210
“Indels were subjected to confirmation via Sanger sequencing [performed as in (34)] which left two of the three pre-filtered indels for further experiments.”
BackgroundMethodInfluentialSelf-citationCancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 217
“The authors demonstrated that a therapeutic pipeline based on neoantigen prediction, curation, and peptide vaccination could prevent tumor growth (48, 49).”
BackgroundRadiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
Rudqvist, N.-P., Pilones, K. A., Lhuillier, C., Wennerberg, E., Sidhom, J.-W., Emerson, R. O., Robins, H. S., Schneck, J., Formenti, S. C., & Demaria, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0134 · Cited by 213
“In the CT26 tumor model, vaccination with neoantigens recognized by CD4þ T cells promoted priming of AH1-specific CD8þ T cells by antigenic spread.”
BackgroundHwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R., Mulders, P., Sheikh, N. A., Trager, J., & Drake, C. G. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 215
“therapy, the immune responses induced or expanded by immunotherapies can spread to include new antigenic targets (27,28).”
BackgroundBest practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 214
“Synthetic long peptides (SLPs) are an effective neoantigen delivery mechanism in personalized immunotherapy pre-clinical studies and clinical trials [30, 101, 130, 131].”
BackgroundNeoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 211
“The recently developed pipeline TIminer (17) integrates cutting-edge bioinformatics tools for the analysis of both, RNA-seq data and somatic DNA mutations in order to characterize the tumor–immune interface.”
MethodWang, W., Xu, H., Ye, Q., Tao, F., Wheeldon, I., Yuan, A., Hu, Y., & Wu, J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00834-6 · Cited by 206
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 200
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
Zuazo, M., Arasanz, H., Fernández‐Hinojal, G., García‐Granda, M. J., Gato, M., Bocanegra, A., Martínez, M., Hernández, B., Teijeira, L., Morilla, I., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910293 · Cited by 198
“Hence, CD4 T cells recognizing tumor neoepitopes contribute significantly to the efficacy of several types of immunotherapies in murine models and in cancer patients (Kreiter et al, 2015; Knocke et al, 2016; Sahin et al, 2017).”
BackgroundTricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
“In particular, neoantigens are considered ideal targets for mobilizing anti-tumor T cell responses against tumor-specific antigens through cancer vaccination or engineered T cells (Carreno et al., 2015; Kreiter et al., 2015; Schumacher and Schreiber, 2015).”
BackgroundApplications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 205
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 203
“However, under some circumstances CD40L might be provided by CD4 T lymphocytes recognizing mutated tumor epitopes, which are frequently detected in mouse and human tumors (Gubin et al., 2014; Kreiter et al., 2015; Linnemann et al., 2015).”
InfluentialIntravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C.-A., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 202
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 200
Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201
Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies
Li, J., Li, J., Peng, Y., Du, Y., Yang, Z., & Qi, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.053 · Cited by 201
Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination
Zeng, Y. C., Young, O. J., Wintersinger, C. M., Anastassacos, F. M., MacDonald, J. I., Isinelli, G., Dellacherie, M. O., Sobral, M., Bai, H., Graveline, A. R., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01615-3 · Cited by 169
“For targeting neoantigens in the murine B16F10 melanoma model, DoriVac was fabricated with B16F10 neoantigen peptides, M27 and M33 (CD8 + responsive) and M30 and M47 (CD4 + responsive) 48,49 (Supplementary Fig.”
Xu, C., Nam, J., Hong, H., Xu, Y., & Moon, J. J. (2019) · ACS Nano · doi:10.1021/acsnano.9b06691 · Cited by 198
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin
Ruf, B., Bruhns, M., Babaei, S., Kedei, N., Ma, L., Revsine, M., Benmebarek, M.-R., Ma, C., Heinrich, B., Subramanyam, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.026 · Cited by 197
Kim, S. P., Vale, N. R., Zacharakis, N., Krishna, S., Yu, Z., Gasmi, B., Gartner, J. J., Sindiri, S., Malekzadeh, P., Deniger, D. C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0040 · Cited by 187
“Various studies have shown that CD4 + T cells can be efficacious in treating cancers in both preclinical and clinical settings (1, 43–46).”
Engineered skin bacteria induce antitumor T cell responses against melanoma
Chen, Y. E., Bousbaine, D., Veinbachs, A., Atabakhsh, K., Dimas, A., Yu, V. K., Zhao, A., Enright, N. J., Nagashima, K., Belkaid, Y., et al. (2023) · Science · doi:10.1126/science.abp9563 · Cited by 191
Metabolic labeling and targeted modulation of dendritic cells
Wang, H., Sobral, M. C., Zhang, D. K. Y., Cartwright, A. N., Li, A. W., Dellacherie, M. O., Tringides, C. M., Koshy, S. T., Wucherpfennig, K. W., & Mooney, D. J. (2020) · Nature Materials · doi:10.1038/s41563-020-0680-1 · Cited by 184
Woller, N., Gürlevik, E., Fleischmann-Mundt, B., Schumacher, A., Knocke, S., Kloos, A. M., Saborowski, M., Geffers, R., Manns, M. P., Wirth, T. C., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.115 · Cited by 186
Clinical and immunological effects of mRNA vaccines in malignant diseases
Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 181
“Kreiter and co-workers [85] demonstrated that the majority of tumor-specific mutations (the “mutanome”) is recognized by CD4+ T cells which confer strong antitumor activity.”
BackgroundParkhurst, M., Gros, A., Pasetto, A., Prickett, T., Crystal, J. S., Robbins, P., & Rosenberg, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2680 · Cited by 182
Barroso-Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 182
“≥3, N (%) 5 (8) 5 (10) 0 (0) 3 (7) 2 (11)”
Tumor immune microenvironment in head and neck cancers
Chen, S. M. Y., Krinsky, A. L., Woolaver, R. A., Wang, X., Chen, Z., & Wang, J. H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23162 · Cited by 179
“Preclinical studies of mouse models have indicated the potential benefits of tumor‐specific neoantigens in immunotherapy.(116,121,122) Results of the therapeutic use of neoantigens in human cancers are also encouraging.”
BackgroundDelivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 177
Targeting mRNA processing as an anticancer strategy
Desterro, J., Bak-Gordon, P., & Carmo-Fonseca, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0042-3 · Cited by 181
Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
Wang, H., Najibi, A. J., Sobral, M. C., Seo, B. R., Lee, J. Y., Wu, D., Li, A. W., Verbeke, C. S., & Mooney, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19540-z · Cited by 172
Forero, A., Li, Y., Chen, D., Grizzle, W. E., Updike, K. L., Merz, N. D., Downs-Kelly, E., Burwell, T. C., Vaklavas, C., Buchsbaum, D. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0243 · Cited by 169
“We are also excited by the possibility that therapies that induce MHC class II expression in tumor cells may be a particularly valuable strategy for converting MHC II–negative poor prognosis TNBC tumors into MHC-positive tumors that present tumor-specific neoantigens (45, 51, 52) and induce antitumor immunity.”
BackgroundThe role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 175
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 177
Chemical Strategies to Boost Cancer Vaccines
Li, W.-H., & Li, Y.-M. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00833 · Cited by 173
Chiang, M.-R., Hsu, C.-W., Pan, W.-C., Tran, N.-T., Lee, Y.-S., Chiang, W.-H., Liu, Y.-C., Chen, Y.-W., Chiou, S.-H., & Hu, S.-H. (2025) · ACS Nano · doi:10.1021/acsnano.4c09525 · Cited by 174
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Jang, S. C., Economides, K. D., Moniz, R. J., Sia, C. L., Lewis, N., McCoy, C., Zi, T., Zhang, K., Harrison, R. A., Lim, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02004-5 · Cited by 162
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
Schaafsma, E., Fugle, C. M., Wang, X., & Cheng, C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01400-2 · Cited by 167
“The importance of HLA class II genes has been shown in the context of ICBT in a number of studies.(61,62) It is proposed that the activation of CD4+ T cells by HLA class II expression helps to initiate CD8+ T cells that consequently mount a successful antitumour immune response during ICBT.”
BackgroundChoucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
Aaes, T. L., & Vandenabeele, P. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00658-y · Cited by 169
Cader, F. Z., Schackmann, R. C. J., Hu, X., Wienand, K., Redd, R., Chapuy, B., Ouyang, J., Paul, N., Gjini, E., Lipschitz, M., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843714 · Cited by 161
De Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J.-Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 165
“In 2015, Kreiter et al.(48) analyzed the mutant peptides in murine tumor cells (e.”
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Brossart, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0305 · Cited by 180
“A recent murine study demonstrated that vaccine-induced cancer neoepitope–specific CD4þ T cells may mediate their antitumor activity by augmentation of CTL responses through epitope spreading indicating that currently developing vaccination strategies that contain neoepitopes derived from mutated antigens can generate…”
ResultMicrobial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
Therapeutic induction of antigen-specific immune tolerance
Kenison, J. E., Stevens, N. A., & Quintana, F. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00970-x · Cited by 179
“Consequently, vaccination with mRNA-encoded epitopes induces potent antigen-specific CD4 + and CD8 + effector T cells 233 . mRNA vaccines have been developed to induce protective immunity against pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 167,168 .”
Shae, D., Baljon, J. J., Wehbe, M., Christov, P. P., Becker, K. W., Kumar, A., Suryadevara, N., Carson, C. S., Palmer, C. R., Knight, F. C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02765 · Cited by 160
Yuzhalin, A. E. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2797 · Cited by 151
Lal, N., White, B. S., Goussous, G., Pickles, O., Mason, M. J., Beggs, A. D., Taniere, P., Willcox, B. E., Guinney, J., & Middleton, G. W. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1090 · Cited by 155
“The majority of immunogenic neoepitopes are class II restricted (7).”
Immunotherapy for Brain Tumors
Sampson, J. H., Maus, M. V., & June, C. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8089 · Cited by 160
“More recently, vaccines that target epitopes that may be recognized by CD4 T cells in the context of major histocompatibility complex class II presentation seem to have shown some promise in preclinical studies.(76,77) However, the mechanism by which these would work in malignant gliomas, which may not”
BackgroundZuo, B., Zhang, Y., Zhao, K., Wu, L., Qi, H., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 155
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 166
“Biomaterials based carriers are expected to achieve the co-delivery of several to tens of exogenous neoantigens together with adjuvants to target APCs, which are necessary for eliciting potent and broad T cell responses to prevent tumor escape in the clinic (16, 17, 20).”
BackgroundHallmarks of Resistance to Immune-Checkpoint Inhibitors
Karasarides, M., Cogdill, A. P., Robbins, P. B., Bowden, M., Burton, E. M., Butterfield, L. H., Cesano, A., Hammer, C., Haymaker, C., Horak, C. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0586 · Cited by 162
“A fascinating observation from preclinical neoantigen vaccination experiments demonstrates that neoantigens predicted based on MHC-I binding characteristics can stimulate CD4þ T-cell responses in excess of CD8þ T-cell responses (50).”
BackgroundYang, Y., Sun, J., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.015 · Cited by 161
Li, Y., Zhang, K., Wu, Y., Yue, Y., Cheng, K., Feng, Q., Ma, X., Liang, J., Ma, N., Liu, G., et al. (2022) · Small · doi:10.1002/smll.202107461 · Cited by 147
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
“Vaccines containing 2–10 neoantigen peptides have been shown to provide long-lasting tumor control in mice, and early clinical work has been promising (Kreiter et al. 2015, Ott et al. 2017).”
BackgroundSasso, M. S., Lollo, G., Pitorre, M., Solito, S., Pinton, L., Valpione, S., Bastiat, G., Mandruzzato, S., Bronte, V., Marigo, I., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.010 · Cited by 147
Zhu, G., Su, H., Johnson, C. H., Khan, S. A., Kluger, H., & Lu, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.053 · Cited by 148
Beyaz, S., Chung, C., Mou, H., Bauer-Rowe, K. E., Xifaras, M. E., Ergin, I., Dohnalová, L., Biton, M., Shekhar, K., Eskiocak, O., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.08.007 · Cited by 155
“Studies have demonstrated that MHC class II-restricted CD4 T cells are able to eradicate tumors both directly and indirectly through the licensing of dendritic cells and helping CD8 T cell responses (Haabeth et al., 2016; Haspot et al., 2014; Hirschhorn-Cymerman et al., 2012; Kreiter et al., 2015; Lu et al., 2017; Spi…”
BackgroundTargeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Sahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 141
“Our group focuses onmutanome-engineered RNA immunotherapy (MERIT) vaccines, which are designed to display multiple neoepitopes separated by nonimmunogenic linkers in a single molecule (34).”
BackgroundSelf-citationT cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 159
“However, there is also strong evidence that CD4 + T cells and, in particular, CD4 + T cells directed against tumor-related antigens and neoantigens, in conjunction with their specific activation, assist the development of anti-tumor immunity 142,143 .”
Role of T cells in cancer immunotherapy: Opportunities and challenges
Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 165
“41 Additionally, the administration of CD4 þ cytotoxic T cells can lead to an anti-tumor response.”
BackgroundDetecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
Liu, Z., Li, J. P., Chen, M., Wu, M., Shi, Y., Li, W., Teijaro, J. R., & Wu, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.048 · Cited by 148
“Intratumoral antigen-specific CD4+ T cells play bidirectional roles in the regulation of antitumor immunity of TSA-reactive CD8+ TILs Intra-tumoral antigen-specific CD4+ T cells have been identified in both patients and murine tumor models (Ahmadzadeh et al., 2019; Alspach et al., 2019; Kreiter et al., 2015; Oh et al.…”
BackgroundCader, F. Z., Hu, X., Goh, W. L., Wienand, K., Ouyang, J., Mandato, E., Redd, R., Lawton, L. N., Chen, P.-H., Weirather, J. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1006-1 · Cited by 142
Van Hoecke, L., Van Lint, S., Roose, K., Van Parys, A., Vandenabeele, P., Grooten, J., Tavernier, J., De Koker, S., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 141
The opposing roles of CD 4+ T cells in anti‐tumour immunity
Ahrends, T., & Borst, J. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 140
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 152
Mass spectrometry-based antigen discovery for cancer immunotherapy
Bassani‐Sternberg, M., & Coukos, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.005 · Cited by 149
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines
Martin, S. D., Brown, S. D., Wick, D. A., Nielsen, J. S., Kroeger, D. R., Twumasi-Boateng, K., Holt, R. A., & Nelson, B. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155189 · Cited by 137
“In one study, a neoantigen-targeted vaccine induced activation of CD4 T cells that mediated rejection of B16F10 melanoma[31].”
BackgroundOba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 147
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
“While this work specifically explores the use of radiation to induce MHC-I neoantigens, we expect that radiation similarly induces MHC-II neoantigens especially because CD4 T cell responses have been shown to be more abundant against neoepitopes in vaccine settings (81, 84).”
BackgroundKang, B., Camps, J., Fan, B., Jiang, H., Ibrahim, M. M., Hu, X., Qin, S., Kirchhoff, D., Chiang, D. Y., Wang, S., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02828-2 · Cited by 155
“Genes associated with peptide presentation via MHC I complexes (R7) [68] and MHC II complexes (R8) [69] were also found to be overexpressed in responders and specifically associated with lymphoid cells and myeloid cells, respectively (Additional file 1: Fig.”
BackgroundComputational tools for modern vaccine development
SUNITA, S., Sajid, A., Singh, Y. P., & Shukla, P. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1670035 · Cited by 154
“An effective vaccine could be designed by the epitope prediction tools as the epitope stimulates immune reactions from both B cells and T cells.(115) Different computational tools such as support vector machines (SVMs), motif-based systems, QSAR (quantitative structure-activity relationship analysis), structure-”
BackgroundThe landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 148
Self-citationNanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 145
Johnson, A. M., Bullock, B. L., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J. W., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 135
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.